CD4 and diabetes mellitus: They reasoned that PD‐L1 presenting microgels promoted a tolerogenic microenvironment by increasing the CD4 Treg population.[85] Though not yet explicitly applied to diabetes therapeutics, functionalized ligands have been shown to locally enhance immune cell populations and provide an avenue for targeted delivery.